Bayer AG shares jumped 6.6% after Orion Corporation, Bayer’s development and commercialization partner for the prostate-cancer drug Nubeqa® (darolutamide), updated its long-term sales outlook. Orion now projects that its portion of annual net sales—comprising tablet sales to Bayer plus royalties—could exceed €1 billion by the end of the decade. This forecast reflects bullish scenario planning for key markets in North America, Europe and Asia, where darolutamide holds approvals in both non-metastatic and metastatic hormone-sensitive prostate cancer. Investors welcomed the potential windfall for Bayer, which records its own share of global revenues from Nubeqa® distribution and co-promotional activities worldwide.

In a corporate strategy update delivered alongside earnings commentary, Bayer outlined a multi-year plan to bolster its pharmaceutical division, with particular emphasis on oncology growth engines such as Nubeqa®. The company committed to increase biopharma R&D investment by €5 billion over the next four years, targeting four late-stage assets in breast, lung and prostate cancer. Bayer also announced a streamlined portfolio review designed to divest two mid-sized non-core therapeutic franchises by mid-2027, freeing up approximately €1 billion in annual operating cash flow for reinvestment. Management highlighted plans to accelerate digital initiatives in clinical development and supply-chain optimization, aiming to improve time-to-market by 20% on future oncology filings.